(TheNewswire)
-
Successful grant comes after recent successfulcompletion of Phase 1 LSD Microdosing LSD Trial in 80participants
-
MindBio working exclusively in psychedelic microdosingclinical trials with University of Auckland research collaborators todevelop IP and novel microdosing treatments
Vancouver, British Columbia – TheNewswire - July 25, 2022 –Blackhawk Growth Corp. (CSE:BLR ) ; ( Frankfurt:0JJ); (OTC:BLRZF) (the “ Company ” or “ Blackhawk ”)subsidiary, MindBio Therapeutics’ (“MindBio”) researchcollaborators at the University of Auckland in New Zealand havereceived NZ$1.44 million in funding from the Health Research Councilof New Zealand to conduct a trial of LSD (Lysergic AcidDiethylamide) microdosing in patients with Major Depressive Disorder.
The grant funding comes after the recent successfulcompletion of a Phase 1 Clinical Trial in 80 healthy participants. The data from this Phase 1 trial is currently being collated andMindBio will make further announcements as information comes tohand.
MindBio is working exclusively in psychedelicmicrodosing clinical trials with scientific collaborators at theUniversity of Auckland to develop intellectual property and novelmicrodosing treatments for mental health conditions that can becommercialized and used to treat patients in the primary health caresystem.
“We are proud of the work of our scientificcollaborators and the substantial support shown is testament to thecalibre of scientists leading the project. We are determined todevelop game-changing treatments for mental health conditions” saidFrederick Pels, CEO of Blackhawk Growth Corp.
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods,Digital Mind Therapeutics, MindBio Therapeutics, Blum DistributorsLtd. as well as an equity position in Gaia Grow Corp.
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
About the University of Auckland
The University of Auckland is Aotearoa NewZealand’s leading university, ranked 87th in the world in the QSWorld Rankings 2022 and sixth in the Times Higher Education UniversityImpact Rankings that measure performance against the Sustainable Development Goals. High-quality research across the full range ofdisciplines, represented by its eight faculties and two Large-ScaleResearch Institutes, ensures its place among the leading internationalresearch universities.
Copyright (c) 2022 TheNewswire - All rights reserved.